|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismHIV replication inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
健康受试者单次、多次口服HRS5685片的安全性、耐受性和药代动力学的I期临床研究
[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of single and multiple oral administration of HRS5685 tablets in healthy subjects
评价HRS5685片在健康受试者中单次和多次给药的安全性与耐受性;
评价HRS5685片在健康受试者中单次给药的药物代谢及药代动力学特征;
评价HRS5685片在健康受试者中多次给药的药代动力学特征。
[Translation] To evaluate the safety and tolerability of single and multiple administrations of HRS5685 tablets in healthy subjects;
To evaluate the drug metabolism and pharmacokinetic characteristics of HRS5685 tablets in healthy subjects after single administration;
To evaluate the pharmacokinetic characteristics of HRS5685 tablets in healthy subjects after multiple administrations.
A Phase I Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
This is a randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose (Part A) and multiple ascending dose (Part B) of HRS5685 tablet in healthy subjects.
100 Clinical Results associated with Recored (Shanghai) Biomedical Co., Ltd.
0 Patents (Medical) associated with Recored (Shanghai) Biomedical Co., Ltd.
100 Deals associated with Recored (Shanghai) Biomedical Co., Ltd.
100 Translational Medicine associated with Recored (Shanghai) Biomedical Co., Ltd.